Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-hydroxyfarnesylphosphonic acid is a synthetic small molecule that acts as a nonhydrolyzable analog of farnesyl pyrophosphate. Its primary mechanism is competitive inhibition of the enzyme farnesyl transferase (FTase), which catalyzes the transfer of a farnesyl group to target proteins such as Ras. By inhibiting FTase activity, this compound can block protein prenylation processes critical for cell signaling and proliferation. It has been used in research settings to study Ras processing and related cellular pathways[1][2][5]. The compound belongs to the class of sesquiterpenoids[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-hydroxyfarnesylphosphonic acid.